Combination antiangiogenic tyrosine kinase inhibition and anti‐PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes

INTRODUCTION: Two separate antiangiogenic tyrosine kinase inhibitors (TKIs) and immunotherapy (IO) combinations are FDA‐approved as front‐line treatment for metastatic renal cell carcinoma (mRCC). Little is known about off‐protocol and post‐front‐line experience with combination TKI–IO approaches. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Laccetti, Andrew L., Garmezy, Benjamin, Xiao, Lianchun, Economides, Minas, Venkatesan, Aradhana, Gao, Jianjun, Jonasch, Eric, Corn, Paul, Zurita‐Saavedra, Amado, Brown, Landon C., Kao, Chester, Kinsey, Emily N., Gupta, Rajan T., Harrison, Michael R., Armstrong, Andrew J., George, Daniel J., Tannir, Nizar, Msaouel, Pavlos, Shah, Amishi, Zhang, Tian, Campbell, Matthew T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982609/
https://www.ncbi.nlm.nih.gov/pubmed/33650321
http://dx.doi.org/10.1002/cam4.3812

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982609/
https://www.ncbi.nlm.nih.gov/pubmed/33650321
http://dx.doi.org/10.1002/cam4.3812

Ejemplares similares